Senate Committee Passes Moderate PBM Reform, But Has Its Eyes On Stronger Policies
Executive Summary
Delinking pharmacy benefits managers’ compensation from the prices of drugs received bipartisan rhetorical support at a HELP markup, but the panel only cleared less drastic PBM reforms along with generic and orphan-drug focused policies. Approved amendments tackled step therapy, pharma transparency and PBM gag clauses, among other topics.
You may also be interested in...
Vanda’s Fourth Suit Against US FDA Claims Agency Shared Its Manufacturing Trade Secrets
Vanda is fighting FDA’s rejection of jet lag indication for Hetlioz as it faces generic competition for sleep-wake disorder treatment. Federal Circuit finds four Hetlioz patents invalid.
Worries About Innovation Incentives Keep Some Generic, Patent Bills Out of HELP Legislation
In a win for the branded industry, just one of the three amendments that caused the initial markup of the Senate Health Committee’s drug pricing legislation to be postponed got included in the package advanced to the floor.
Senate HELP Panel’s Confounded Markup Points To Challenges Ahead For Chairman Sanders
Session on PBM and generic legislation brought to a halt by Republican objections to amendments targeting FDA disclosure of inactive ingredient concentrations in brands, method-of-use patents, and using REMS to extend patent protection.